Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study

BACKGROUND: The incidence and mortality rates of patients with chronic lymphocytic leukemia (CLL) in China have recently increased. This study performed a long-term economic evaluation of the first-line treatment strategies ibrutinib (IB) or bendamustine (BE) plus rituximab (RI) for previously untre...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Yuan, Chen, Xichuang, Hong, Yuanquan, Xiao, Xingfang, Wang, Yan, You, Xiaohong, Mi, Jingyi, Zhou, Tao, Zheng, Panpan, Huang, Zhihu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696775/
https://www.ncbi.nlm.nih.gov/pubmed/38049834
http://dx.doi.org/10.1186/s12913-023-10402-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696775/
https://www.ncbi.nlm.nih.gov/pubmed/38049834
http://dx.doi.org/10.1186/s12913-023-10402-0

Ejemplares similares